Polycythemia epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
*The [[incidence]] of [[polycythemia vera]] is approximately 1.9 per 100,000 individuals in the United States. | *The [[incidence]] of [[polycythemia vera]] is approximately 1.9 per 100,000 individuals in the United States. | ||
*Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. | *Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females. | ||
===Prevalence=== | ===Prevalence=== | ||
*The [[prevalence]] of [[Polycythemia vera|polycythemia vera i]]<nowiki/>n the 7 MM countries was 283,442 in 2017. | *The [[prevalence]] of [[Polycythemia vera|polycythemia vera i]]<nowiki/>n the 7 MM countries was 283,442 in 2017. | ||
*[[Prevalence]] of [[polycythemia vera]] was the highest in the US in 2017 at 157,290, out of which 62,916 cases were [[asymptomatic]] and 94,374 were [[symptomatic]]. | *[[Prevalence]] of [[polycythemia vera]] was the highest in the US in 2017 at 157,290, out of which 62,916 cases were [[asymptomatic]] and 94,374 were [[symptomatic]]. | ||
*22 cases per 100,000 people. | *22 cases per 100,000 people. | ||
===Case-fatality rate/Mortality rate=== | ===Case-fatality rate/Mortality rate=== | ||
| Line 24: | Line 24: | ||
*On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | *On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average. | ||
*[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often. | *[[Comorbidities]] such as [[cardiovascular]] diseases, other blood, and [[lymphatic]] disorders, [[vascular]] disorders, mass occupying lesions in the [[thorax]], respiratory system, infections, etc. accounted for more deaths more often. | ||
*[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]]. | *[[Thrombosis|Thrombotic]] complications were the most common cause of death followed by [[hematologic]] [[malignancy]]. | ||
===Age=== | ===Age=== | ||
*It has been noted that PV is more common in the age group >75. | *It has been noted that PV is more common in the age group >75. | ||
*Median age of diagnosis is 60.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | *Median age of diagnosis is 60.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | ||
===Race=== | ===Race=== | ||
*Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. | *Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians. | ||
===Gender=== | ===Gender=== | ||
*Generally, there is no sex predilection.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | *Generally, there is no sex predilection.<ref name="pmid32491592">{{cite journal |vauthors=Lu X, Chang R |title= |journal= |volume= |issue= |pages= |date= |pmid=32491592 |doi= |url=}}</ref> | ||
*In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. | *In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females. | ||
===Region=== | ===Region=== | ||
Revision as of 16:22, 2 March 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Polycythemia epidemiology and demographics |
|
Risk calculators and risk factors for Polycythemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
- Not usually diagnosed in individuals below 60 years of age. Slightly more prevalent in men than in women according to some studies.
Epidemiology and Demographics
Incidence
- The incidence of polycythemia vera is approximately 1.9 per 100,000 individuals in the United States.
- Taking into account all races and ethnicities, the incidence is approximately 2.8 per 100,000 males and 1.3 per 100,000 in females.
Prevalence
- The prevalence of polycythemia vera in the 7 MM countries was 283,442 in 2017.
- Prevalence of polycythemia vera was the highest in the US in 2017 at 157,290, out of which 62,916 cases were asymptomatic and 94,374 were symptomatic.
- 22 cases per 100,000 people.
Case-fatality rate/Mortality rate
- 4-year mortality rate is >10%.
- On average patients lived with the disease for 8.6 years (mean), the cases that were fatal were approximately 77.1 years of age on average.
- Comorbidities such as cardiovascular diseases, other blood, and lymphatic disorders, vascular disorders, mass occupying lesions in the thorax, respiratory system, infections, etc. accounted for more deaths more often.
- Thrombotic complications were the most common cause of death followed by hematologic malignancy.
Age
- It has been noted that PV is more common in the age group >75.
- Median age of diagnosis is 60.[1]
Race
- Jews of Eastern European descent have a higher number of cases as compared to other Europeans or Asians.
Gender
- Generally, there is no sex predilection.[1]
- In the analysis for the 7 MM countries, the percentage of prevalent males was higher than prevalent females.
Region
References
- ↑ 1.0 1.1 1.2 Lu X, Chang R. PMID 32491592 Check
|pmid=value (help). Missing or empty|title=(help) - ↑ Johansson P (April 2006). "Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia". Semin Thromb Hemost. 32 (3): 171–3. doi:10.1055/s-2006-939430. PMID 16673273.